Sarclisa Induction Boosts Progression-Free Survival in Transplant-Eligible Multiple Myeloma
Recent findings from the two-part, double-randomized GMMG-HD7 phase 3 study reveal that Sarclisa (isatuximab), combined with lenalidomide, bortezomib, and dexamethasone (RVd), significantly enhances progression-free survival (PFS) in newly diagnosed, transplant-eligible…
Novartis Wins FDA Approval for Fabhalta®, First Complement Inhibitor for IgAN
Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor designed to reduce proteinuria in adults with primary immunoglobulin…
Lilly Q2 2024: Financial Results & $3B Revenue Guidance Boost
Eli Lilly today announced its Q2 2024 financial results, highlighting strong performance driven by Mounjaro, Zepbound, and Verzenio, along with significant advancements in global manufacturing. David A. Ricks, Lilly’s chair…
Novo Nordisk’s Sales Up 24% to DKK 133.4 Billion in First Half of 2024
Operating profit rose by 18% in Danish kroner and 19% at constant exchange rates (CER) to DKK 57.8 billion, despite a DKK 5.7 billion impairment loss related to ocedurenone. North…
Rite Aid Now Offering Flu and RSV Vaccine Appointments at All Locations
Rite Aid Announces Flu and RSV Vaccine Appointments Available at All Locations Rite Aid has announced that appointments for both influenza (flu) and respiratory syncytial virus (RSV) vaccines are now…
Professional Pickleball Player James Ignatowich Teams Up with IBSA USA to Advocate for Licart
Professional Pickleball Association (PPA Tour) player James Ignatowich has teamed up with IBSA USA to promote Licart® (diclofenac epolamine) topical system 1.3%. Licart is the only once-a-day topical nonsteroidal anti-inflammatory…
Alzamend Neuro and Mass General Launch Phase II Trial of AL001 for Alzheimer’s
Alzamend Neuro, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, announced its partnership with Massachusetts General Hospital…
ILiAD Biotechnologies Named to Fierce Biotech’s 2024 Fierce 15
ILiAD Biotechnologies, a biotech company developing the most advanced next-generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the company to its Fierce 15 2024 list, recognizing ILiAD…
Imbrium Therapeutics Submits New Drug Application to Investigate Sunobinop for Alcohol Use Disorder Treatment
Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate sunobinop…
Salubris Biotherapeutics Receives EMA Approval to Launch Phase 1 Clinical Trial of 5T4-Targeted ADC JK06 in Solid Tumors
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a…
Bayer Achieves Primary Endpoint in Phase III FINEARTS-HF Study of KERENDIA® for Heart Failure
Bayer announced today that the FINEARTS-HF trial met its primary endpoint by achieving a statistically significant reduction in the composite of cardiovascular death and total (first and recurrent) heart failure…
U.S. Oligonucleotide Synthesis Market Report 2024-2030: Trends, Shares, and Analysis
The “U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report” for 2024-2030 has been added to ResearchAndMarkets.com’s portfolio. This report forecasts that the U.S. oligonucleotide synthesis market will reach…